Indira IVF Announces Global Research Collaboration on Sperm DNA Double-Strand Breaks and Male Infertility

“Male infertility remains an important area of focus in reproductive medicine, with several aspects of sperm health and their clinical impact still requiring deeper investigation,” said Dr. Kshitiz Murdia, Chief Executive Officer and Whole-Time Director of Indira IVF Hospital Limited, on Wednesday.

The Mumbai-headquartered fertility provider announced a four-way international research collaboration on International Men’s Day to run prospective clinical studies on the role of sperm double-strand DNA breaks (DSBs) in assisted reproductive technology (ART) outcomes, BW Health reported. Partners include Androfert of Brazil, Bonraybio Co. Ltd. of Taiwan, and ADVY Bioscience Private Limited of India.

Standard Analysis Misses Sperm DNA Breaks

  • Standard semen analysis counts sperm and checks motility, but it cannot see breaks in the DNA strands inside the sperm head.
  • Double-strand breaks are the most severe form of DNA damage; they may allow fertilisation but derail embryo development or implantation.
  • This study aims to define the exact threshold of breaks that lowers live-birth rates, so clinics can choose the right ART technique — or advise donor sperm — before a couple spends time and money on a cycle likely to fail.

Why Sperm DNA Integrity Matters Now

Male factors account for roughly 40 per cent of infertility cases globally. Conventional semen parameters — concentration, morphology, progressive motility — correlate poorly with live-birth rates after intracytoplasmic sperm injection (ICSI).

Sperm DNA fragmentation (SDF) testing fills part of that gap, yet most commercial assays (SCSA, TUNEL, Comet) report total fragmentation without distinguishing single-strand from double-strand breaks. Single-strand breaks are largely repaired by the oocyte; double-strand breaks overwhelm the oocyte’s repair machinery, leading to chromosomal aberrations, arrested embryos, or miscarriage.

Epidemiological urgency sharpens the question. According to Global Burden of Disease data cited by Swadesi News, male infertility prevalence in South Asia surged nearly 47 per cent between 1990 and 2021.

India recorded the steepest rise in the region — almost 59 per cent — concentrated among men in their late 20s. Environmental toxicants, heat exposure, varicocele, and oxidative stress from lifestyle factors are hypothesised drivers, but prospective clinical evidence linking DSB thresholds to ART outcomes remains thin.

Indira IVF Partners for Male Infertility Research
Photo: swadesi.com

Study Design and Partner Roles

The collaboration was formalised after discussions at the American Society for Reproductive Medicine (ASRM) Annual Meeting 2025 in San Antonio. Prof. Sandro C. Esteves, Medical Director of Androfert and a globally recognised authority on male infertility, will co-lead the initiative with Dr. Vipin Chandra, who directs the investigation from Indira IVF.

Indira IVF will lead clinical recruitment, provide semen and embryo samples, and supply the analytical framework. Bonraybio contributes its specialised diagnostic platform for quantifying sperm genomic integrity, including DSB-specific assays. ADVY Bioscience supports the translational research ecosystem linking bench validation to clinical workflows.

“Advancements in reproductive medicine require accurate and reliable diagnostic technologies,” said Brown Hsu, CEO of Bonraybio. “Through this collaboration, we look forward to supporting the generation of clinical evidence that may contribute to a better understanding of sperm genomic integrity and its impact on reproductive outcomes.”

Chetan Raj Singh, President of ADVY Bioscience, added that the partnership aims to connect translational research with clinical applications in male reproductive health. “By validating these diagnostic approaches, we aim to support more informed and effective treatment pathways.”

Diagnostic Changes: What Patients Face Now

Current SDF testing is recommended selectively — typically after recurrent implantation failure, recurrent pregnancy loss, or unexplained infertility — by guidelines from the European Association of Urology (EAU) and the American Urological Association (AUA). However, no consensus exists on which assay to use or what cut-off value should trigger a change in management, such as switching from IVF to ICSI, using testicular sperm extraction (TESE), or employing antioxidant therapy.

Assay Type DNA Lesion Detected Typical Clinical Cut-off (DFI %) Limitation Regarding DSBs
Comet Assay (Alkaline vs Neutral) Alkaline: total breaks; Neutral: primarily DSBs No universal standard Neutral Comet isolates DSBs but lacks high-throughput clinical validation
Bonraybio Platform (Investigational) Targeted DSB quantification Under study Prospective threshold correlation with live birth is primary endpoint of this trial

If the Indira IVF–Androfert–Bonraybio–ADVY programme establishes a validated DSB threshold, clinicians could stratify patients before the first ART cycle. Men above the threshold might proceed directly to testicular sperm extraction (which yields sperm with lower DSB loads) or receive targeted antioxidant and varicocele repair protocols before attempting ejaculated-sperm ICSI.

Funding, Governance, and Bias Transparency

The announcement does not disclose a grant amount, public funding source, or independent data-monitoring committee. Indira IVF, a private hospital chain, leads clinical operations and supplies the patient cohort. Bonraybio and ADVY Bioscience are commercial diagnostic entities whose platforms stand to gain regulatory and market traction from positive findings.

Prof. Esteves holds a leadership role at Androfert, a private andrology clinic. Readers should interpret forthcoming publications with these commercial affiliations in mind; peer-reviewed manuscripts should declare funding, protocol registration numbers, and statistical analysis plans.

Testing Not for All Men; See Specialist If

Sperm DNA fragmentation testing — including emerging DSB-specific assays — is not a first-line screen for all men. It is generally contraindicated as a routine pre-conception test in couples with no history of infertility, normal semen parameters, and no recurrent loss, because false positives may drive unnecessary invasive procedures. Men should seek specialist evaluation if:

  • Conception has not occurred after 12 months of regular unprotected intercourse (6 months if the female partner is > 35 years).
  • Semen analysis reveals oligozoospermia, asthenozoospermia, or teratozoospermia.
  • The couple has experienced two or more failed ICSI cycles or recurrent miscarriages.
  • Clinical varicocele, history of chemotherapy, or occupational toxin exposure is present.

A reproductive urologist or fertility specialist can determine whether SDF or DSB testing adds actionable information to the standard work-up.

Researchers Will Link DSB Metrics to Live-Birth Outcomes

The investigators plan to enrol couples undergoing ART at Indira IVF centres across India, correlating baseline DSB metrics with fertilisation rates, blastulation rates, euploidy status on pre-implantation genetic testing for aneuploidy (PGT-A), and ultimately live-birth rates.

Prof. Esteves said the research would examine how double-strand DNA breaks influence fertilisation and embryo viability. “By generating evidence on the thresholds at which these breaks may become clinically significant, we hope to strengthen understanding of male infertility and enable science-driven fertility care.”

Until then, clinicians should continue to follow EAU/AUA guidance: reserve SDF testing for selected indications, counsel couples on the limits of current evidence, and avoid over-interpreting single-assay results.

References

  • Practice Committee of the American Society for Reproductive Medicine. “The clinical utility of sperm DNA integrity testing: a guideline.”, 2023.
  • Esteves SC, et al. “Sperm DNA fragmentation testing: summary evidence and clinical practice recommendations.”, 2021.
  • Agarwal A, et al. “Global prevalence of male infertility and trends: a systematic review and meta-analysis.”, 2022.
  • World Health Organization., 6th ed., 2021.
Photo of author

Health Desk

Health Desk at Archyde.

Officials Say at Least 24 Dead as Boat Carrying Mourners Capsizes in Nigeria

Mallorca’s Lone Town Crier Revives Tradition in Maria de la Salut